Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Clovis Oncology Inc (CLVS)

Clovis Oncology Inc (CLVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 382,138
  • Shares Outstanding, K 129,979
  • Annual Sales, $ 164,520 K
  • Annual Income, $ -369,210 K
  • 60-Month Beta 1.69
  • Price/Sales 2.50
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade CLVS with:

Options Overview Details

View History
  • Implied Volatility 93.27%
  • Historical Volatility 44.97%
  • IV Percentile 63%
  • IV Rank 20.76%
  • IV High 248.67% on 01/08/21
  • IV Low 52.56% on 08/10/21
  • Put/Call Vol Ratio 0.28
  • Today's Volume 2,873
  • Volume Avg (30-Day) 4,510
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 61,183
  • Open Int (30-Day) 62,836

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -0.56
  • Number of Estimates 4
  • High Estimate -0.32
  • Low Estimate -0.96
  • Prior Year -0.74
  • Growth Rate Est. (year over year) +24.32%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.93 +0.34%
on 12/01/21
4.76 -38.24%
on 11/02/21
-1.62 (-35.53%)
since 11/01/21
3-Month
2.93 +0.34%
on 12/01/21
4.97 -40.85%
on 09/02/21
-1.98 (-40.24%)
since 09/01/21
52-Week
2.93 +0.34%
on 12/01/21
11.10 -73.51%
on 02/08/21
-1.93 (-39.63%)
since 12/01/20

Most Recent Stories

More News
AstraZeneca, Merck's Lynparza sNDA Gets FDA Priority Tag

FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) sNDA for Lynparza for BRCA-mutated HER2-negative high-risk early breast cancer.

AZN : 54.88 (+0.09%)
GSK : 41.37 (+0.61%)
MRK : 74.44 (-0.63%)
CLVS : 2.94 (-6.96%)
Clovis (CLVS) Q3 Loss Wider Than Expected, Revenues Lag

Clovis (CLVS) reports wider-than-expected loss for third-quarter 2021. Sales of the company's sole marketed drug, Rubraca, declined year over year owing to COVID-19 impacts.

REGN : 630.59 (-0.93%)
BMY : 54.95 (+2.46%)
ALKS : 21.47 (-2.05%)
CLVS : 2.94 (-6.96%)
Clovis Oncology (CLVS) Reports Q3 Loss, Lags Revenue Estimates

Clovis (CLVS) delivered earnings and revenue surprises of -16.67% and -2.11%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

CLVS : 2.94 (-6.96%)
Global Metastatic Cancer Treatment Market Size Is Forecasted To Reach $111.16 Million By 2027

Palm Beach, FL – November 3, 2021 – FinancialNewsMedia.com News Commentary – The metastatic cancer treatment systems market is observing high demand attributed to its increasing application in breast,...

ONCY : 1.5700 (-7.10%)
ONC.TO : 2.03 (-5.14%)
CLVS : 2.94 (-6.96%)
MRK : 74.44 (-0.63%)
AZN : 54.88 (+0.09%)
ARAY : 4.81 (unch)
Clovis: Q3 Earnings Snapshot

BOULDER, Colo. (AP) _ Clovis Oncology Inc. (CLVS) on Wednesday reported a loss of $67.4 million in its third quarter.

CLVS : 2.94 (-6.96%)
Clovis Oncology Announces Third Quarter 2021 Operating Results

Clovis Oncology , Inc. (NASDAQ:CLVS) reported financial results for the quarter ended September 30, 2021, and provided an update on the Company’s clinical development programs and regulatory and commercial...

CLVS : 2.94 (-6.96%)
Clovis Oncology to Announce Third Quarter 2021 Financial Results and Host Webcast Conference Call on November 3

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its third quarter 2021 financial results on Wednesday, November 3, 2021, before the open of the US financial markets. Clovis’ senior management will...

CLVS : 2.94 (-6.96%)
Clovis Oncology and ITM Announce Lutetium-177 Clinical Supply Agreement

Clovis Oncology, Inc. (NASDAQ: CLVS) and ITM Isotope Technologies Munich SE , a leading radiopharmaceutical biotech company, today announced the signing of a clinical supply agreement that provides Clovis...

CLVS : 2.94 (-6.96%)
Clovis (CLVS) Focuses on Rubraca Growth Amid Rising Competition

Clovis Oncology's (CLVS) sole marketed drug Rubraca has been approved for multiple cancer indications. Yet, the drug's sales remain tepid on account of competition from PARP inhibitors.

BMY : 54.95 (+2.46%)
PFE : 54.68 (+1.77%)
MRK : 74.44 (-0.63%)
CLVS : 2.94 (-6.96%)
Pan-Cancer Analysis Suggests Fibroblast Activation Protein (FAP) is an Attractive Target for Peptide-Targeted Radionuclide Therapy with FAP-2286

Clovis Oncology, Inc. (NASDAQ: CLVS) announced that nonclinical data describing the expression of fibroblast activating protein (FAP) in a variety of solid tumor types will be presented during the AACR-NCI-EORTC...

CLVS : 2.94 (-6.96%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Clovis Oncology Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. The Company targets its development programs for the treatment of specific subsets of cancer populations....

See More

Key Turning Points

3rd Resistance Point 3.51
2nd Resistance Point 3.39
1st Resistance Point 3.17
Last Price 2.94
1st Support Level 2.82
2nd Support Level 2.70
3rd Support Level 2.48

See More

52-Week High 11.10
Fibonacci 61.8% 7.98
Fibonacci 50% 7.02
Fibonacci 38.2% 6.05
Last Price 2.94
52-Week Low 2.93

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar